Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.47 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.47 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.40 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.37 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.37 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.37 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439222 | 0.98 | — | — | |
| SCHEMBL29261172 | 0.96 | LMNA (0.51) | LMNARAB9ADHODHNPC1GMNN | |
| Acetic Acid SCHEMBL28353986 | 0.94 | LMNA (0.50) | LMNARAB9ADHODHNPC1GMNN | |
| SCHEMBL27318417 | 0.84 | RAB9A (0.50) | LMNARAB9ADHODHNPC1GMNN | |
| SCHEMBL9395508 | 0.84 | LMNA (0.43) | LMNARAB9ADHODHNPC1GMNN | |
| SCHEMBL27969576 | 0.82 | LMNA (0.50) | LMNARAB9ADHODHNPC1GMNN | |
| Hydrochloric Acid SCHEMBL30684514 | 0.81 | LMNA (0.46) | LMNARAB9ADHODHNPC1GMNN | |
| SCHEMBL335045 | 0.80 | — | — | |
| 4-Chloroaniline SCHEMBL11667673 | 0.80 | RAB9A (0.43) | LMNARAB9ADHODHNPC1GMNN | |
| 4-Bromoaniline SCHEMBL11664501 | 0.80 | RAB9A (0.41) | LMNARAB9ADHODHNPC1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257270-B1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMA (IL) | 2005-04-13 | — | — | EP | claimed |
| US-20040127532-A1 | Method for synthesizing leflunomide | AVRUTOV ILYA (IL) | 2004-07-01 | — | — | US | claimed |
| US-6723855-B2 | CHLORINATING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID BY REACTING WITH CHLORINATING AGENT TO FORM 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID CHLORIDE, REACTING WITH 4-TRIFLUOROMETHYLANILINE IN PRESENCE OF ALKALI METAL OR ALKALINE EARTH METAL BICARBONATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-04-20 | — | — | US | claimed |
| JP-2004500380-A | — | — | 2004-01-08 | — | — | JP | claimed |
| CN-1120160-C | Isoxazole and crotonamide derivatives and their use as pharmaceuticals and disgnositics | AVENTIS PHARMACEUTICAL DEUTSCH (DE) | 2003-09-03 | — | — | CN | claimed |
| EP-1257270-A4 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMA (IL) | 2003-05-07 | — | — | EP | claimed |
| EP-1257270-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-11-20 | — | — | EP | claimed |
| US-20020022646-A1 | Method for systhesizing leflunomide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-02-21 | — | — | US | claimed |
| WO-2001060363-A1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-08-23 | — | — | WO | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2007086076-A2 | AN IMPROVED PROCESS FOR PREPARATION OF LEFLUNOMIDE | UNICHEM LABORATORIES LIMITED (IN) | 2007-08-02 | — | — | WO | disclosed |
| EP-1257270-B1 | A METHOD FOR SYNTHESIZING LEFLUNOMIDE | TEVA PHARMA (IL) | 2005-04-13 | — | — | EP | disclosed |
| EP-1473035-A1 | Leflunomide of high purity | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-03 | — | — | EP | disclosed |
| US-20040127532-A1 | Method for synthesizing leflunomide | AVRUTOV ILYA (IL) | 2004-07-01 | — | — | US | disclosed |
| US-4117145-A | DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | disclosed |
| US-4117143-A | USED AS ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | disclosed |
| US-4113872-A | DIURETICS, SALURETICS, ANTIHYPERTENSIVE, ANTITHROMBOTIC AGENTS | BAKER AKTIENGESELLSHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4113957-A | DIURETIC, SALURETIC, HYPOTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4112109-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4099011-A | DIURETIC, SALURETIC, HYPOTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022646-A1 | Method for systhesizing leflunomide | FAH, LEF1, HMGCR | HTR1A 3542/4885MAOA 2703/4885SLC6A2 2865/4885 |
| US-20040127532-A1 | Method for synthesizing leflunomide | LEF1, CYP3A5, CYP2F1 | HTR1A 2847/4885MAOA 1276/4885SLC6A2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.